26th April 2022 | Pharma Updates

PharmaState Updates – Latest Pharma Happenings

Kotaro Suzuki named Managing Director of OMRON Healthcare India

Kotaro Suzuki has been appointed as the new Managing Director of OMRON Healthcare India, a key participant in the digital home blood pressure monitoring industry.

Manipal Hospitals awarded the first ERAS certification in SE Asia

Manipal Hospitals has received the ERAS certification as the first healthcare provider in Southeast Asia. Oncology, Gynecology, and Gastroenterology all benefit greatly from this therapy.

Care Hospitals acquires 100% share in Thumbay for Rs 40 crore

Care Hospitals Group announced that it has purchased 100% stake in Thumbay Hospital New Life, Malakpet, Hyderabad, for Rs 40 crore as part of its efforts to expand its footprint in the city’s northern reaches.

Access Healthcare for Medical Products L.L.C. acquired entirely by Marksans Pharma

Marksans Pharma Limited has agreed to buy a 100% investment in Access Healthcare for Medical Products L.L.C, a Dubai-based front-marketing and promotion firm.

Big Pharma investors must ensure equal access of COVID-19 vaccines

Amnesty International said that investors in companies that make Covid-19 vaccines must use their clout to ensure that critically needed lifesaving vaccines reach low- and lowermiddle-income countries.

Pfizer's blood pressure drug recall spreads to the United States

After testing revealed quantities of a nitrosamine—N nitroso-quinapril— above recommended daily limits, Pfizer is recalling five lots of Accupril pills, commonly known as quinapril HCL.

Veklury approved by FDA for the treatment of COVID-19 in children

Gilead Sciences announced that the FDA had approved a supplemental new drug application (sNDA) for Veklury (remdesivir) for the treatment of paediatric patients with COVID-19

USFDA expected to reject Axsome's migraine medication

Axsome Therapeutics (AXSM.O) said on Monday that it expects US Food and Drug Administration to reject its medication for acute migraine due to unresolved quality control issues.